Side Effect Profile of Arimidex vs. Femara: A Comparison Study
Side Effects of Arimidex vs. Femara
DOI:
https://doi.org/10.61919/jhrr.v4i3.1488Keywords:
Arimidex, Femara, aromatase inhibitors, breast cancer, postmenopausal women, side effects, HR+ breast cancer, musculoskeletal pain, cardiovascular health, bone density loss, endocrine therapy, patient compliance.Abstract
Background: Background: Aromatase inhibitors, Arimidex (anastrozole) and Femara (letrozole), are commonly used in the treatment of hormone receptor-positive (HR+) breast cancer in postmenopausal women. Despite similar efficacy, these drugs have different side effect profiles that impact patient compliance and quality of life.
Objective: To compare the incidence and severity of side effects between Arimidex and Femara in postmenopausal women with HR+ breast cancer.
Methods: A retrospective cohort study was conducted involving 1,000 postmenopausal women with HR+ breast cancer from multiple oncology centers. Participants were divided into two groups: Arimidex (n=500) and Femara (n=500). Side effects were assessed via patient self-reports, clinical evaluations, and standardized questionnaires. Data were analyzed using chi-square tests, t-tests, and logistic regression models, with p-values <0.05 considered significant.
Results: Arimidex was associated with higher rates of joint pain (45% vs. 30%, p<0.001) and muscle pain (38% vs. 25%, p<0.01). Femara showed increased rates of hypertension (28% vs. 20%, p<0.05) and significant bone density loss (18% vs. 12%, p<0.05).
Conclusion: Arimidex and Femara exhibit distinct side effect profiles, suggesting the need for personalized treatment approaches based on patient risk factors.
Downloads
References
Bell SG. Aromatase Inhibitor Use, Side Effects and Discontinuation Rates in Gynecologic Oncology Patients. Gynecologic Oncology. 2020;159(2):509-514.
Zhao F. Toxicity of Extended Adjuvant Endocrine Therapy with Aromatase Inhibitors in Patients with Postmenopausal Breast Cancer: A Systematic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology. 2020;156:103114.
Robertson JF. Meta-Analyses of Phase 3 Randomised Controlled Trials of Third Generation Aromatase Inhibitors Versus Tamoxifen as First-Line Endocrine Therapy in Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer. European Journal of Cancer. 2021;145:19-28.
Peddie N. The Impact of Medication Side Effects on Adherence and Persistence to Hormone Therapy in Breast Cancer Survivors: A Qualitative Systematic Review and Thematic Synthesis. The Breast. 2021;58:147-159.
Cucciniello L. Estrogen Deprivation Effects of Endocrine Therapy in Breast Cancer Patients: Incidence, Management and Outcome. Cancer Treatment Reviews. 2023;120:102624.
Aggarwal S. Drug Repurposing for Breast Cancer Therapy: Old Weapon for New Battle. Seminars in Cancer Biology. 2021;68:8-20.
Cucciniello L. Tailoring Adjuvant Endocrine Therapy in Early Breast Cancer: When, How, and How Long? Cancer Treatment Reviews. 2022;110:102445.
Malik JA. Drugs Repurposed: An Advanced Step Towards the Treatment of Breast Cancer and Associated Challenges. Biomedicine & Pharmacotherapy. 2022;145:112375.
Moscetti L. Quality of Life of Therapies for Hormone Receptor Positive Advanced/Metastatic Breast Cancer: Regulatory Aspects and Clinical Impact in Europe. The Breast. 2021;59:232-238.
Fasching PA. Prognostic Impact of Selection Criteria of Current Adjuvant Endocrine Therapy Trials NATALEE and MonarchE in Postmenopausal HRpos/HER2neg Breast Cancer Patients Treated with Upfront Letrozole. European Journal of Cancer. 2024;209:114239.
Yang L. The Effect of Exemestane Administration on the Lipid Profile in Women: Meta-Analysis of Randomized Controlled Trials. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2024;295:25-33.
Rochoy M. Doping with Aromatase Inhibitors and Oestrogen Receptor Modulators in Steroid Users: Analysis of a Forum to Identify Dosages, Durations and Adverse Drug Reactions. Therapies. 2022;77(6):683-691.
W. MB EM. Management of Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. Seminars in Oncology. 2020;47(4):187-200.
Hasson SP. Adjuvant Endocrine Therapy in HER2-Positive Breast Cancer Patients: Systematic Review and Meta-Analysis. ESMO Open. 2021;6(2):100088.
Taheri H. Quantification of the Aromatase Inhibitor Letrozole and Its Carbinol Metabolite in Mouse Plasma by UHPLC-MS/MS. Journal of Chromatography B. 2024;1238:124106.
Bhatia N. Selective Estrogen Receptor Degraders (SERDs) for the Treatment of Breast Cancer: An Overview. European Journal of Medicinal Chemistry. 2023;256:115422.
McAndrew NP. Management of ER Positive Metastatic Breast Cancer. Seminars in Oncology. 2020;47(5):270-277.
P BSc CL. Effect of Traditional Chinese Medicine on Musculoskeletal Symptoms in Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Pain and Symptom Management. 2021;62(1):159-173.
Battisti NML. Systemic Therapy for Older Patients with Early Breast Cancer. Cancer Treatment Reviews. 2021;100:102292.
Khan J. Exploring Triazole-Based Drugs: Synthesis, Application, FDA Approvals, and Clinical Trial Updates – A Comprehensive Review. Tetrahedron. 2024;162:134122.
Rani S. A Review on Diverse Heterocyclic Compounds as the Privileged Scaffolds in Non-Steroidal Aromatase Inhibitors. Bioorganic Chemistry. 2021;113:105017.
Meattini I. Omission of Radiation Therapy After Breast-Conserving Surgery for Biologically Favourable Tumours in Younger Patients: The Wrong Answer to the Right Question. Radiotherapy and Oncology. 2024;190:110045.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sanila Rafique, Faisal Mehmood, Amna, Maria Ahmed, Tayyaba Sajjad, Muhammad Farrukh Habib
This work is licensed under a Creative Commons Attribution 4.0 International License.
